SG Americas Securities
NGNE icon

SG Americas Securities’s Neurogene NGNE Stock Holding History

SG Americas Securities’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,576
Closed -$150K – 3448
2024
Q3 		$150K Buy
+3,576
New +$139K ﹤0.01% 2737
2024
Q2 		– Sell
-2,348
Closed -$120K – 3154
2024
Q1 		$120K Buy
+2,348
New +$78.4K ﹤0.01% 2411
2021
Q4 		– Sell
-1,117
Closed -$162K – 3666
2021
Q3 		$162K Buy
+1,117
New +$171K ﹤0.01% 3371
2020
Q4 		– Sell
-6,431
Closed -$1.54M – 3429
2020
Q3 		$1.54M Buy
6,431
+5,622
+695% +$1.36M 0.01% 923
2020
Q2 		$269K Buy
+809
New +$211K ﹤0.01% 2600
2017
Q1 		– Sell
-394
Closed -$130K – 3472
2016
Q4 		$130K Buy
+394
New +$106K ﹤0.01% 2679

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG Americas Securities's NGNE Position: Q4 2024 in Review

SG Americas Securities sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 3,576 shares — an estimated $150K sold.

SG Americas Securities first reported a position in NGNE in Q4 2016 and held it in 6 quarters. The position peaked at $1.54M in Q3 2020. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • SG Americas Securities reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • SG Americas Securities sold 3,576 Neurogene shares in Q4 2024, an estimated $150K.
  • SG Americas Securities first reported a position in Neurogene in Q4 2016 and held it in 6 quarters.
  • SG Americas Securities's Neurogene position peaked at $1.54M in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on SG Americas Securities's 13F filing for Q4 2024, filed 17 Jan 2025.